Cargando…

Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats

Ethnopharmacological relevance: Serpylli herba extract (SHE), composed of the aerial parts of wild thyme (Thymus serpyllum L.) (Lamiaceae family), is traditionally used in Europe and North Africa to treat diarrhea, gastric ulcers, intestinal parasites and upper respiratory tract infections. Recently...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Malagón, Antonio Jesús, Rodríguez-Sanchez, María José, Rodríguez-Sojo, María Jesús, Vezza, Teresa, Pischel, Ivo, Algieri, Francesca, Rodríguez-Cabezas, María Elena, Rodríguez-Nogales, Alba, Gálvez, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479127/
https://www.ncbi.nlm.nih.gov/pubmed/36120292
http://dx.doi.org/10.3389/fphar.2022.967644
_version_ 1784790721317830656
author Ruiz-Malagón, Antonio Jesús
Rodríguez-Sanchez, María José
Rodríguez-Sojo, María Jesús
Vezza, Teresa
Pischel, Ivo
Algieri, Francesca
Rodríguez-Cabezas, María Elena
Rodríguez-Nogales, Alba
Gálvez, Julio
author_facet Ruiz-Malagón, Antonio Jesús
Rodríguez-Sanchez, María José
Rodríguez-Sojo, María Jesús
Vezza, Teresa
Pischel, Ivo
Algieri, Francesca
Rodríguez-Cabezas, María Elena
Rodríguez-Nogales, Alba
Gálvez, Julio
author_sort Ruiz-Malagón, Antonio Jesús
collection PubMed
description Ethnopharmacological relevance: Serpylli herba extract (SHE), composed of the aerial parts of wild thyme (Thymus serpyllum L.) (Lamiaceae family), is traditionally used in Europe and North Africa to treat diarrhea, gastric ulcers, intestinal parasites and upper respiratory tract infections. Recently, SHE has generated a great interest for irritable bowel syndrome (IBS) management, probably due to its intestinal anti-inflammatory properties shown in experimental colitis and the fact that its active components could preserve the intestinal barrier integrity, which is altered in patients with IBS. Aim of study: We aimed to test the effects of a SHE in a rat experimental model resembling human IBS. Materials and methods: IBS was provoked by deoxycholic acid (DCA). Rats were then treated with SHE (100 mg/kg) or gabapentin (70 mg/kg) and different inflammatory and gut barrier integrity markers were evaluated. Moreover, several gut hypersensitivity and hyperalgesia determinations were performed. Results: SHE improved referred pain and visceral hypersensitivity. Additionally, SHE enhanced immune status by downregulating of the expression of the pro-inflammatory mediators Il-1β, Il-6, Ifn-γ, Tlr-4, and the inducible enzyme Cox-2, thus inducing visceral analgesia, and promoting the restore of the gut barrier function by upregulating the mucins Muc-2 and Muc-3. These anti-inflammatory effects could be related to its action on mast cells since it significantly inhibited the β-Hexosaminidase production in RBL-2H3 cells. Lastly, SHE also seems to modulate the serotonin pathway by restoring the altered expression of the 5-HT receptors Htr-3 and Htr-4. Conclusion: SHE could be considered a potential new treatment for IBS, since it ameliorates hypersensitivity, visceral hyperalgesia, and inflammation. These beneficial effects may be due to the inhibition of mast cells degranulation and serotonin pathway.
format Online
Article
Text
id pubmed-9479127
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94791272022-09-17 Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats Ruiz-Malagón, Antonio Jesús Rodríguez-Sanchez, María José Rodríguez-Sojo, María Jesús Vezza, Teresa Pischel, Ivo Algieri, Francesca Rodríguez-Cabezas, María Elena Rodríguez-Nogales, Alba Gálvez, Julio Front Pharmacol Pharmacology Ethnopharmacological relevance: Serpylli herba extract (SHE), composed of the aerial parts of wild thyme (Thymus serpyllum L.) (Lamiaceae family), is traditionally used in Europe and North Africa to treat diarrhea, gastric ulcers, intestinal parasites and upper respiratory tract infections. Recently, SHE has generated a great interest for irritable bowel syndrome (IBS) management, probably due to its intestinal anti-inflammatory properties shown in experimental colitis and the fact that its active components could preserve the intestinal barrier integrity, which is altered in patients with IBS. Aim of study: We aimed to test the effects of a SHE in a rat experimental model resembling human IBS. Materials and methods: IBS was provoked by deoxycholic acid (DCA). Rats were then treated with SHE (100 mg/kg) or gabapentin (70 mg/kg) and different inflammatory and gut barrier integrity markers were evaluated. Moreover, several gut hypersensitivity and hyperalgesia determinations were performed. Results: SHE improved referred pain and visceral hypersensitivity. Additionally, SHE enhanced immune status by downregulating of the expression of the pro-inflammatory mediators Il-1β, Il-6, Ifn-γ, Tlr-4, and the inducible enzyme Cox-2, thus inducing visceral analgesia, and promoting the restore of the gut barrier function by upregulating the mucins Muc-2 and Muc-3. These anti-inflammatory effects could be related to its action on mast cells since it significantly inhibited the β-Hexosaminidase production in RBL-2H3 cells. Lastly, SHE also seems to modulate the serotonin pathway by restoring the altered expression of the 5-HT receptors Htr-3 and Htr-4. Conclusion: SHE could be considered a potential new treatment for IBS, since it ameliorates hypersensitivity, visceral hyperalgesia, and inflammation. These beneficial effects may be due to the inhibition of mast cells degranulation and serotonin pathway. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9479127/ /pubmed/36120292 http://dx.doi.org/10.3389/fphar.2022.967644 Text en Copyright © 2022 Ruiz-Malagón, Rodríguez-Sanchez, Rodríguez-Sojo, Vezza, Pischel, Algieri, Rodríguez-Cabezas, Rodríguez-Nogales and Gálvez. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ruiz-Malagón, Antonio Jesús
Rodríguez-Sanchez, María José
Rodríguez-Sojo, María Jesús
Vezza, Teresa
Pischel, Ivo
Algieri, Francesca
Rodríguez-Cabezas, María Elena
Rodríguez-Nogales, Alba
Gálvez, Julio
Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats
title Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats
title_full Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats
title_fullStr Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats
title_full_unstemmed Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats
title_short Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats
title_sort intestinal anti-inflammatory and visceral analgesic effects of a serpylli herba extract in an experimental model of irritable bowel syndrome in rats
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479127/
https://www.ncbi.nlm.nih.gov/pubmed/36120292
http://dx.doi.org/10.3389/fphar.2022.967644
work_keys_str_mv AT ruizmalagonantoniojesus intestinalantiinflammatoryandvisceralanalgesiceffectsofaserpylliherbaextractinanexperimentalmodelofirritablebowelsyndromeinrats
AT rodriguezsanchezmariajose intestinalantiinflammatoryandvisceralanalgesiceffectsofaserpylliherbaextractinanexperimentalmodelofirritablebowelsyndromeinrats
AT rodriguezsojomariajesus intestinalantiinflammatoryandvisceralanalgesiceffectsofaserpylliherbaextractinanexperimentalmodelofirritablebowelsyndromeinrats
AT vezzateresa intestinalantiinflammatoryandvisceralanalgesiceffectsofaserpylliherbaextractinanexperimentalmodelofirritablebowelsyndromeinrats
AT pischelivo intestinalantiinflammatoryandvisceralanalgesiceffectsofaserpylliherbaextractinanexperimentalmodelofirritablebowelsyndromeinrats
AT algierifrancesca intestinalantiinflammatoryandvisceralanalgesiceffectsofaserpylliherbaextractinanexperimentalmodelofirritablebowelsyndromeinrats
AT rodriguezcabezasmariaelena intestinalantiinflammatoryandvisceralanalgesiceffectsofaserpylliherbaextractinanexperimentalmodelofirritablebowelsyndromeinrats
AT rodrigueznogalesalba intestinalantiinflammatoryandvisceralanalgesiceffectsofaserpylliherbaextractinanexperimentalmodelofirritablebowelsyndromeinrats
AT galvezjulio intestinalantiinflammatoryandvisceralanalgesiceffectsofaserpylliherbaextractinanexperimentalmodelofirritablebowelsyndromeinrats